Instituto BioMar S.A., León, Spain

Under a Collaborative Research Agreement, Aphios is utilizing its SuperFluids™ fractionation technology for the fast and selective separation of secondary metabolites from marine microorganisms. These fractions have been tested for anti-HIV activity by Aphios and anti-cancer activity by BioMar. Twenty (20) microbes were found to be active against HIV-1; the most active has been scaled-up by Aphios Corporation for SuperFluids™ fractionation, chemistry and further development.

Instituto BioMar, S.A., a Spanish Corporation, headquartered in Leon, Spain, has an extensive marine microorganisms library and performs drug research on compounds and extracts in the field of biological activity for therapeutic and pharmaceutical use and development of commercial products by third parties. BioMar’s fields of interest include antitumor, antiviral (including anti-HIV), immunoregulator, fungal and antidiabetic retinopathy.